| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8211889 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(2 years from now) | |
| US7538108 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Mar, 2026
(2 years from now) | |
| US7989448 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(2 years from now) | |
| US8163902 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(2 years from now) | |
| US7449458 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Sep, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9266912 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(2 years from now) | |
| USRE48898 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(2 years from now) | |
| US8445485 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(2 years from now) | |
| US9283238 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(2 years from now) | |
| US8912170 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(2 years from now) | |
| US8652492 | RIGEL PHARMS INC | Wet granulation using a water sequestering agent |
Nov, 2028
(5 years from now) | |
| US8263122 | RIGEL PHARMS INC | Wet granulation using a water sequestering agent |
Nov, 2030
(7 years from now) | |
| US8771648 | RIGEL PHARMS INC | (Trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(8 years from now) | |
| US8951504 | RIGEL PHARMS INC | (trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(8 years from now) | |
Tavalisse is owned by Rigel Pharms Inc.
Tavalisse contains Fostamatinib Disodium.
Tavalisse has a total of 14 drug patents out of which 0 drug patents have expired.
Tavalisse was authorised for market use on 17 April, 2018.
Tavalisse is available in tablet;oral dosage forms.
Tavalisse can be used as treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment.
Drug patent challenges can be filed against Tavalisse from 2022-04-17.
The generics of Tavalisse are possible to be released after 27 July, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 17, 2025 |
| New Chemical Entity Exclusivity (NCE) | Apr 17, 2023 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: 2022-04-17
Market Authorisation Date: 17 April, 2018
Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment
Dosage: TABLET;ORAL
TAVALISSE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic